Stay up-to-date on new clinical findings in Skin Cancer View the latest articles, case reports, supplements, Podcast episodes and more!
In this edition of the JDD podcast “Ask the Investigator,” host Dr. Adam Friedman from the GW School of Medicine and Health Sciences is joined by Dr. Evan Rieder, Assistant Professor of Dermatology at NYU Langone Medical Center and one of the few dermatologists double board certified in dermatology and psychiatry in the U.S., to discuss his recent study entitled “Dermatologist Practices During Total Body Skin Examinations: A Survey Study.” Do we all do it the same? Are we all checking every nook and cranny? Do we need better standardization for our greatest weapon to enable early and life saving skin cancer detection? Call me crazy, but this is pretty…..preeeetty… pretty important (as Larry David would say).
Basal cell carcinomas (BCC) arise from DNA damage to cells of the basal layer of the epidermis and most commonly in areas of the skin exposed to sunlight or ultraviolet radiation. BCC is the most common skin cancer seen in humans with over 4.3 million cases reported in the United States and is responsible for 3-10% of all cancers annually. We report what we believe to be the first case of this very prevalent skin cancer arising in the nasal vestibule. The lesion was treated with Mohs micrographic surgery and required three stages to obtain histological clearance. Given the location of the tumor, Mohs surgery was chosen due to the procedure’s effectiveness for achieving the highest cure rate with the lowest incidence of tumor recurrence and for preserving as much adjacent healthy tissue as possible
Standard of care for squamous cell carcinoma (SCC) is usually surgical, with either excision or Mohs micrographic surgery. However, surgery may not be ideal for elderly patients with numerous lesions, who are poor surgical candidates or who refuse surgery. Topical 5-fluorouracil (5-FU) and imiquimod have been studied off-label as monotherapies in the treatment of SCC in situ with promising results. However, long-term tumor-free survival rates are still less than with surgical management.
Here we report a case of linear porokeratosis with recurrent malignant degeneration to squamous cell carcinoma (SCC) recurring six years after excision of initial SCC. A 79-year-old woman presented with a friable tumor located within a longstanding lesion on her posterior thigh. Six years prior, she was diagnosed with SCC arising within the same lesion, which had been surgically excised with negative margins. Physical examination revealed a 3.5 x 2.7 cm friable tumor on the left proximal posterior thigh.
Following a diagnosis of cutaneous malignant melanoma (CMM), patients are often guided for subsequent management by their dermatologist and national guideline recommendations. Based upon staging classification for CMM, guidelines recommend diagnostic tests and additional evaluation which may provide defined treatment protocols, surveillance, and follow-up.
Actinic keratoses (AKs) are precancerous, dysplastic epidermal lesions with potential for progression to squamous cell carcinoma (SCC). A study by Criscione et al1 revealed that in a high-risk population (≥2 keratinocyte carcinomas in previous 5 years), approximately 65% of all primary SCCs arose in lesions previously diagnosed as AKs. Furthermore, it demonstrated that the risk of malignant progression of AKs to primary SCC increases over time (0.6% at 1 year and 2.6% at 4 years).1 Cellular damage and atypia seen histologically in AKs are similar to those of surrounding nonlesional skin,2,3 suggesting that skin surrounding AKs may have an increased risk of skin cancer.
Multiple primary melanomas (MPMs) have been reported to occur in 2-10% of melanoma patients. This study conducted a review of the literature to elucidate the definitions of terminology used to describe MPMs that were diagnosed in close temporal proximity as well as explore common risk factors. Terminology found in the literature included “concurrent”, “simultaneous” and “synchronous” with varying definitions that ranged from 0-6 months between diagnoses of the first and subsequent melanomas. Eight cases are described in chronological order, and the incidence of MPMs diagnosed around the same time were reported as 22-39%. Nevus spilus was identified as a potential risk factor for MPMs. This study highlights that MPMs are not uncommon, and clinicians should remain aware that MPMs can be diagnosed at or around the same time, warranting thorough skin exams.
Supportive oncodermatology is a growing field that provides treatment and preventive care to oncology patients who experience dermatologic adverse events (dAEs) secondary to cytotoxic and targeted cancer treatments. Novel cancer therapies that impede the proliferation of cancer cells often target other rapidly proliferating organ systems and can lead to unfavorable skin, hair, and nail alterations. The most commonly documented dAEs include papulopustular rash, xerosis, pruritus, nail changes, chemotherapy-induced alopecia, and hand-foot skin reaction.1,2 Persistent dermatologic side effects may be disabling and are associated with negative psychosocial effects affecting patient confidence and functionality.3-6 Further, over 50% of cancer patients experience an interruption in therapy secondary to dAEs.7 With an estimated 1.8 million new cancer diagnoses made in 2019,8 all patients receiving anticancer therapy may be vulnerable to dAEs and the consequent impacts on wellness and treatment adherence.
The American Cancer Society reported that Cancer remains leading cause of death in Hispanics. Lung cancer for men and breast for women. Non-melanoma skin cancer (NMSC) is the most common malignancy in the United States, over 3.5 million in over 2 million people, incidence rising at about 2.6% per year.
© 2020 JDDonline - Journal of Drugs in Dermatology. Copyright © 2020 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
